Xencor (XNCR) Stock: Buy, Sell, or Hold?
XNCR - Xencor, Inc.
$24.41
0.15 (0.62%)
â˛
5d:
-8.3%
30d:
+5.31%
90d:
+101.9%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When XNCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: XNCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: XNCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: XNCR is currently trading at $24.41, which is considered fair relative to its 30-day fair value range of $21.77 to $27.91.
Technical Outlook: Technically, XNCR is in a strong uptrend. The price is currently testing key support at $23.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XNCR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.08 (+23.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XNCR is in a strong uptrend. The price is currently testing key support at $23.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XNCR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.08 (+23.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$21.77 -
$27.91
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.2% below Wall St target ($30.08)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$21.77 -
$27.91
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$23.86
Resistance Level
$28.98
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.88
Wall Street Target
$30.08
(+23.2%)
Revenue Growth (YoY)
17.5%
Profit Margin
-155.6%
Share & Embed Analysis
Last updated: September 13, 2026 3:29 AM ET
Data refreshes hourly during market hours. Next update: 4:29 AM
Data refreshes hourly during market hours. Next update: 4:29 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XNCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
